Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.44 |
| ▸ | APP | P05067 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | AGXT | P21549 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6477647 | 0.88 | MAOB (0.50) | ABCB1MAOBMAPTSMN1; SMN2IDO1 | |
| SCHEMBL6477273 | 0.87 | HTR2A (0.47) | RAB9AMAOBMAPTALDH1A1HPGD | |
| SCHEMBL6473179 | 0.86 | PTPN1 (0.45) | APPNPC1RAB9AMAOBMAPT | |
| SCHEMBL6477668 | 0.86 | CCR5 (0.46) | MAOBMAPTLMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL6473566 | 0.81 | LIPE (0.42) | ABCB1APPNPC1RAB9AMAOB | |
| SCHEMBL6916157 | 0.80 | RXRA (0.47) | NPC1RAB9AMAOBSMN1; SMN2HDAC8 | |
| SCHEMBL8887456 | 0.78 | NPC1 (0.42) | ABCB1APPNPC1RAB9AMAOB | |
| SCHEMBL629337 | 0.77 | HTR2A (0.52) | RAB9AMAOBMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL5366510 | 0.77 | RXRA (0.45) | L3MBTL1 | |
| SCHEMBL24855495 | 0.77 | L3MBTL1 (0.52) | APPNPC1RAB9AMAOBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924388-B2 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-02 | — | — | US | disclosed |
| US-20040092594-A1 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-05-13 | — | — | US | disclosed |
| US-6632963-B1 | Are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2003-10-14 | — | — | US | disclosed |
| EP-0947496-B1 | Bicyclic aromatic compounds and their use in human and veterinary medicine as well as in cosmetology | GALDERMA RES & DEV (FR) | 2002-10-09 | — | — | EP | disclosed |
| EP-0947496-A1 | Bicyclic aromatic compounds and their use in human and veterinary medicine as well as in cosmetology | Galderma Research & Development, S.N.C. (FR) | 1999-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092594-A1 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | AHR, TYR, MC1R | ABCB1 2044/4885APP 2281/4885NPC1 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.